John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 9,400 shares at $163.89 ($1.5M) on 2021-11-01, disclosed to the SEC on 2021-11-03.
Open-market sale of $1.5M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $160.33 | 100 | $16K | 1.0% |
| 2 | $160.75 | 100 | $16K | 1.0% |
| 3 | $161.52 | 100 | $16K | 1.1% |
| 4 | $163.10 | 1,494 | $244K | 15.8% |
| 5 | $163.10 | 1,494 | $244K | 15.8% |
| 6 | $163.89 | 2,906 |
| $476K |
| 31.0% |
| 7 | $163.89 | 2,906 | $476K | 31.0% |
| 8 | $164.58 | 300 | $49K | 3.2% |
| Total | $163.56 avg | 9,400 | $1.5M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |